Inactive Instrument

Highlights Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Concert Pharmaceuticals Announces the Presentation of Data from its Phase 3 Clinical Trial, THRIVE-AA2	23-03-18	CI
Sun Pharmaceutical Completes Acquisition of Concert Pharmaceuticals	23-03-06	MT
Sun Pharmaceutical Industries Limited completed the acquisition of Concert Pharmaceuticals, Inc..	23-03-05	CI
Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	23-02-15	CI
Indian shares set for muted start on rate hike concerns	23-01-19	RE
Sun Pharmaceutical to Acquire US-Based Concert Pharmaceuticals in $576 Million Deal	23-01-19	MT
Concert Pharmaceuticals Shares Rally on Takeover by Sun	23-01-19	DJ
Concert Pharmaceuticals to Merge with Sun Pharmaceutical; Shares Rise Pre-Bell	23-01-19	MT
Sun Pharmaceutical to Buy Concert Pharmaceuticals For Initial $576 Million	23-01-19	DJ
India's Sun Pharma to acquire Concert for $8 per share	23-01-19	RE
Sun Pharmaceutical Industries Limited executed a definitive agreement to acquire Concert Pharmaceuticals, Inc. for approximately $510 million.	23-01-18	CI
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib Thrive-Aa1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research	22-11-21	CI
Concert Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI
Earnings Flash (CNCE) CONCERT PHARMACEUTICALS Reports Q3 Revenue $8,000, vs. Street Est of $80,000	22-11-07	MT
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress	22-09-10	CI
Concert Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Earnings Flash (CNCE) CONCERT PHARMACEUTICALS Reports Q2 Revenue $21,000	22-08-04	MT
Concert Pharmaceuticals Reports Positive Topline Results in Hair Loss Trial; Shares Soar	22-08-01	MT
Concert Pharmaceuticals, Inc. Reports Positive Topline Results for Second CTP-543 Phase 3 Clinical Trial in Alopecia Areata	22-08-01	CI
Concert Pharmaceuticals, Inc. Announces the Publication of Safety and Efficacy Data from the Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Phase 2 Clinical Trial for CTP-543	22-06-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Highlights

Filters